Assessing Sarcopenia in Advanced-Stage Ovarian Cancer Patients Undergoing Neoadjuvant Chemotherapy: A Case Series.
Christelle SchofieldDennis R TaaffeRobert U NewtonDaniel A GalvãoPaul A CohenJin-Soo KimTarek MeniawyCarolyn Peddle-McIntyrePublished in: Cancer reports (Hoboken, N.J.) (2024)
Ovarian cancer patients with low muscle mass during neoadjuvant chemotherapy may not be identified as sarcopenic based on the EWGSOP2 diagnostic algorithm. While lacking a universally accepted definition for cancer-related sarcopenia and cancer-specific recommendations for the screening, diagnosis, and treatment of sarcopenia, ovarian cancer clinicians should focus on the diagnosis and treatment of low muscle mass and density.